Europe allows exemption for medical CFCs :
This article was originally published in Clinica
Executive Summary
Continued exemptions for some medical applications are included in updated European legislation on ozone-depleting substances which has cleared its final stages in the European Parliament. A new regulation will allow national governments to permit the use of CFCs until December 31 2004 "in delivery mechanisms for hermetically sealed devices designed for implantation in the human body for delivery of measured doses of medication". The regulation will replace existing EU legislation on Europe's implementation of the Vienna convention for the protection of the ozone layer and the Montreal protocol on substances that deplete the ozone layer. The current 1994 regulation will be replaced by the new text on October 1. The regulation is directly binding and applies in all member states.
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.